Akebia Therapeutics (AKBA) has released an update.
Akebia Therapeutics, Inc. has amended its retention and separation agreements with Chief Operating Officer Michel Dahan and Senior Vice President Nicole R. Hadas, extending their separation dates to June 28, 2024, and June 14, 2024, respectively. These changes indicate strategic adjustments within the company’s leadership team, potentially signaling a focus on stability and continuity as it approaches significant corporate milestones.
For further insights into AKBA stock, check out TipRanks’ Stock Analysis page.
